Plan costs increase to unsustainable levels, threatening a plans solvency Pain Point : GLP-1 medications, while effective for diabetes and weight loss, drive up health care costs for employers and their self-funded plans
"Offering Zepbound single-dose vialsthe most affordable branded incretin medicine by list pricethrough another platform to LillyDirect will help ensure broader availability of rigorously tested, FDA-approved and regulated obesity treatment," said Patrik Jonsson, executive vice president, and president of Lilly Cardiometabolic Health and Lilly USA in a statement
T., Leslie, J., Ross, M., Mann, D
This result implicates enhanced resilience against the energetic strain imposed by ischemic disease as a mechanistic account of GLP-1-mediated cardioprotection
With simple planning, people using GLP-1 medications can continue their treatment safely while enjoying trips and holidays
Your clinician will weigh risks and benefits and may suggest a different plan if GLP-1s arent a fit
